NLS PHARMACEUTICS LTD (NLSP) Stock Analyst Ratings
USA - NASDAQ:NLSP - CH1384053976 - Common Stock
0.762 USD
+0.02 (+2.97%)
1.08 USD
+0.32 (+41.73%)
ChartMill assigns a Buy % Consensus number of 43% to NLSP. The Buy consensus is the weighted average rating of the current analysts ratings.
NLSP was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about NLSP.
In the previous month the buy percentage consensus was at a similar level.
NLSP was analyzed by 6 analysts. More opinions would make the average more meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-09-14 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-12-08 | Maxim Group | Upgrade | Hold -> Buy |
| 2022-11-08 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-09-06 | Laidlaw & Co. | Initiate | Buy |
| 2021-03-12 | Brookline Capital | Initiate | Buy |
| 2021-03-03 | Maxim Group | Initiate | Buy |
NLS PHARMACEUTICS LTD / NLSP FAQ
Can you provide the consensus rating for NLS PHARMACEUTICS LTD stock?
The consensus rating for NLS PHARMACEUTICS LTD (NLSP) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
How many analysts have analysed NLS PHARMACEUTICS LTD (NLSP)?
The number of analysts covering NLS PHARMACEUTICS LTD (NLSP) is 6.